VidPrevtyn Beta ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

vidprevtyn beta

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - Ваксини - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 и 5. 1 in product information document). Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Betaklav 500 mg/125 mg film - coated tablets  বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

betaklav 500 mg/125 mg film - coated tablets 

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 500 mg/125 mg film - coated tablets 

Betaklav 875 mg/125 mg film - coated tablets  বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

betaklav 875 mg/125 mg film - coated tablets 

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 875 mg/125 mg film - coated tablets 

Betaklav 400 mg/57 mg/5 ml powder for oral suspension বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

betaklav 400 mg/57 mg/5 ml powder for oral suspension

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 400 mg/57 mg/5 ml powder for oral suspension

Cevenfacta ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - Антихеморагични - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.